Expand BCRX Menu
BCRX MENU

BCRX Latest Press Releases

-- April 15, 2026 --

BioCryst to Report First Quarter 2026 Financial Results on May 6 Globe Newswire 7:00 AM

-- April 6, 2026 --

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer Globe Newswire 7:00 AM

-- April 3, 2026 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- March 4, 2026 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- February 26, 2026 --

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update Globe Newswire 7:00 AM

-- February 17, 2026 --

BioCryst to Present at Upcoming Investor Conference Globe Newswire 7:00 AM

-- February 11, 2026 --

BioCryst to Present New HAE Data from ORLADEYO (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting Globe Newswire 7:00 AM

-- February 5, 2026 --

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 Globe Newswire 7:01 AM
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- January 23, 2026 --

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema Globe Newswire 9:00 AM

-- January 12, 2026 --

BioCryst Announces Preliminary Full Year 2025 ORLADEYO (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range Globe Newswire 7:00 AM

-- January 7, 2026 --

Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS PRNewswire 5:12 PM

-- January 6, 2026 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM

-- December 12, 2025 --

BioCryst Announces FDA Approval of ORLADEYO (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years Globe Newswire 7:00 AM

-- December 4, 2025 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- December 3, 2025 --

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes